Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03812510 · ClinicalTrials.gov registry record · Phase 3
Safety Study of A-101 Topical Solution for the Treatment of Common Warts
A Phase 3 study of Common Wart, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
- 20
- Study locations
NCT03812510 is a Phase 3 study of Common Wart that has completed, run by Aclaris Therapeutics. The registered enrollment target is 426 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT03812510, a Phase 3 study of Common Wart, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
Conditions Studied
Interventions
- DRUG A-101
Study Locations (20)
Florida
- Aclaris Investigational Site - Aventura
- Aclaris Investigational Site - Jacksonville
- Aclaris Investigational Site - Miami
- Aclaris Investigational Site - Miami
- Aclaris Investigational Site - Ocala
California
- Aclaris Investigational Site - Encinitas
- Aclaris Investigational Site - Fountain Valley
- Aclaris Investigational Site - San Diego
- Aclaris Investigational Site - San Diego
Arkansas
- Aclaris Investigational Site - Fort Smith
- Aclaris Investigational Site - Hot Springs
Indiana
- Aclaris Investigational Site - Indianapolis
- Aclaris Investigational Site - New Albany
Alabama
- Aclaris Investigational Site - Mobile
Arizona
- Aclaris Investigational Site - Glendale
Colorado
- Aclaris Investigational Site - Denver
Georgia
- Aclaris Investigational Site - Newnan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2019-12-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03812510
The ClinicalTrials.gov registry entry for NCT03812510 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Common Wart appearing as the primary indexed condition, and to 1 intervention - of which A-101 is the first listed.
NCT03812510 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03812510 about?
NCT03812510 is a clinical study titled "Safety Study of A-101 Topical Solution for the Treatment of Common Warts". A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
What is the current status of trial NCT03812510?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2019-02-07. Estimated completion is 2019-12-20.
What conditions does trial NCT03812510 study?
This clinical trial studies the following conditions: Common Wart.
What interventions are being tested in trial NCT03812510?
The interventions under investigation include: A-101 (DRUG).
Who is sponsoring clinical trial NCT03812510?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03812510 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Wart
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.